BioPharmSignal logoBioPharmSignal

Biotech News

Liquidia Corporation Reports First Quarter 2026 Financial Results

Liquidia Corporation (LQDA)Liquidia Corporation2026-06-25 13:46 ESTEarnings

YUTREPIA ® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between launch in June 2025 and April 30, 2026 Recorded third consecutive quarter of

Open original release

Related news

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026

LQDALiquidia Corporation2026-06-25 13:46 EST

Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

View all latest news

Liquidia Corporation

Liquidia is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

LQDALiquidia Corporation2026-06-26 08:20 EST

Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions

LQDALiquidia Corporation2026-06-26 08:20 EST

Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index

LQDALiquidia Corporation2026-06-26 08:20 EST

Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference

LQDALiquidia Corporation2026-06-26 08:20 EST

Liquidia Corporation Reports First Quarter 2026 Financial Results

LQDALiquidia Corporation2026-06-26 08:20 EST

Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States